Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Praxis Precision Medicines ( (PRAX) ) has shared an announcement.
Praxis Precision Medicines is advancing its CNS disorder therapies, with promising developments in its late-stage drugs: relutrigine for developmental and epileptic encephalopathies, ulixacaltamide for essential tremor, and vormatrigine for epilepsy. The company is expanding its EMBOLD study and planning new trials, supported by strong financials and a focus on precision medicine. These efforts highlight significant progress towards potentially transformative treatments in the neurological space.
See more insights into PRAX stock on TipRanks’ Stock Analysis page.
